EXOSYSTEMS' exoRehab Receives CES Innovation Recognition
AI-powered wearable enhances home rehabilitation for users.
EXOSYSTEMS Inc. recently announced that their groundbreaking product, exoRehab, has been honored as a CES Innovation Awards 2026 Honoree in the Digital Health category. During CES, taking place from January 6 to January 9, live demonstrations will exhibit the functionality of this transformative Remote Therapeutic Monitoring (RTM) solution designed for musculoskeletal care.
Empowering Rehabilitation at Home
Rehabilitation after surgery or injury can be challenging for many patients, leading to inconsistent recovery progress. exoRehab combines a user-friendly mobile application with a web dashboard and a lightweight wearable device. This synergy creates a comprehensive at-home exercise program while allowing clinicians to remotely monitor their patients' progress. The wearable device is designed to capture essential muscle activity (surface EMG) and movement data (IMU) directly from the skin. Using EXOSYSTEMS' proprietary Muscle Function Index (MFI), the device provides valuable insights into muscle performance and movement trends, enabling patients and healthcare providers to track advancements or setbacks in real-time and adjust exercise regimens when necessary.
Transforming Subjective Observations into Objective Insights
Central to EXOSYSTEMS' innovation is the Muscle Function Index (MFI), a proprietary neuromuscular digital biomarker developed through a collaborative study with Roche Korea. This tool stands out due to its ability to deliver accurate, reproducible motor function metrics within a mere five minutes, replacing tedious and variable assessments traditionally conducted in clinics.
Benefits for Patients and Clinicians
exoRehab is designed to cater to various needs:
- Patients: Receive straightforward home exercise instructions, real-time feedback, and experience faster recovery, reducing the number of unnecessary clinic visits.
- Clinicians: Benefit from precise data regarding muscle performance and movement, enabling early detection of potential issues like stiffness or weakness, and simplifying documentation processes.
- Participating Clinics: Patients can consult with their healthcare providers to learn about the availability and pilot programs related to exoRehab.
- Health Systems and Research Teams: Gain standardized data and assessments that contribute to demonstrating effective treatments, offering beneficial insights for quality care and evidence generation.
Aligning with U.S. Care Standards
Designed to fit seamlessly into existing workflows, exoRehab supports Remote Therapeutic Monitoring (RTM) structures in U.S. clinics and complies with the appropriate CPT codes. This ensures that healthcare teams can effectively track patient engagement and therapeutic activities while simplifying documentation for reimbursement processes.
Live Demonstration at CES
Visitors to CES can engage with EXOSYSTEMS' representatives, who will conduct hands-on demonstrations of the exoRehab wearable technology, showcasing live muscle signals through the app and illustrating guided exercises tailored for home rehabilitation. This event will take place at the Venetian Expo, Level 2 - Global Pavilion, Hall A - Booth 50017.
A Vision for Rehabilitation
Hooman Lee, CEO of EXOSYSTEMS, shared, "We designed exoRehab to empower patients to visually grasp their recovery journey, not simply rely on feelings of improvement. By providing objective data on muscle performance, we facilitate everyday wins that can be tracked by both patients and clinicians together."
About EXOSYSTEMS
EXOSYSTEMS is an innovative medical AI company specializing in the development of neuromuscular digital biomarkers and personalized digital therapeutics. The centerpiece of our technology is the Muscle Function Index (MFI), which quantifies neuromuscular performance based on biosignals to analyze muscle function comprehensively. MFI has gained recognition in peer-reviewed journals and has been designated as an Innovative Medical Device by Korea's MFDS, underscoring its significance in AI medical software applied to sarcopenia diagnosis.
As we prepare to launch exoRehab, we are excited to integrate MFI to provide accurate assessments and personalized rehabilitation strategies, employing wearables for electronic muscle stimulation across different body areas. The therapeutic effects of our tailored digital solutions have been highlighted in various health journals.
Founded in 2017 by Hooman Lee, who holds a degree from Seoul National University and has a background in research at ETRI, EXOSYSTEMS has garnered support from venture capitalists and manages an impressive portfolio of national R&D initiatives exceeding $10 million.
Frequently Asked Questions
What is exoRehab?
exoRehab is a digital health solution that combines wearable technology with a mobile app to enhance rehabilitation practices at home.
How does exoRehab benefit patients?
It offers real-time feedback, clear instructions, and helps track recovery progress, reducing unnecessary clinic visits.
Who developed the Muscle Function Index?
The Muscle Function Index was developed by EXOSYSTEMS in collaboration with Roche Korea.
Where can I see exoRehab in action?
Live demonstrations will be available at CES 2026 in Las Vegas at the Venetian Expo.
How long has EXOSYSTEMS been in operation?
EXOSYSTEMS was founded in 2017 and has since been focusing on advancing the field of neuromuscular digital therapeutics.
